Evidence map›Paper›PMID 42231038›Full record

ReviewMicrobiologyOpen2026

Nanoparticle-Based Strategies to Combat Multidrug-Resistant Bacteria: Mechanisms, Applications, and Future Perspectives.

Akmal Zubair, Syeda Zaira Batool, Mohamed H Helal, Naila Afghan

Abstract readReview
In one paragraph

Review in MicrobiologyOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Akmal ZubairDepartment of Biotechnology, Quaid-i-Azam University Islamabad, Pakistan.ORCID https://orcid.org/0000-0002-1165-8305
Syeda Zaira BatoolDepartment of Biotechnology, Quaid-i-Azam University Islamabad, Pakistan.
Mohamed H HelalCenter for Scientific Research and Entrepreneurship, Northern Border University, Arar, Saudi Arabia.
Naila AfghanDepartment of Biology, Kabul University, Kabul, Afghanistan.

Funding

Northern Border University, Saudi Arabia NBU-CRP-2026-540
6 · The paper itself

Abstract

The infectious diseases remain a primary cause of morbidity and mortality on a global level, a crisis exacerbated by the rapid emergence of antimicrobial resistance (AMR). The ineffectiveness of the old antibiotics and the stagnation of the development of new medications have triggered an emergency in the search for new methods of treatment. This review examines the opportunity of nanotechnology, which is the so-called nanobiotics, as a game-changing technology in combating multidrug-resistant (MDR) bacteria by searching various databases. Nanoparticles (NPs) are unique physicochemicals, i.e., high surface-to-volume ratio and multi-valent properties that enable them to overcome traditional resistance, e.g., efflux pumps, target modifications. The paper discusses the important antibacterial processes, which can involve the induction of oxidative stress by the production of reactive oxygen species (ROS), the physical destabilization of the bacterial cell envelope, or the targeting of intracellular macromolecules, such as DNA and proteins. Moreover, it emphasizes the synergistic nature of the interactions of NPs with traditional antibiotics to improve drug delivery and efficacy and decrease host toxicity. Although a wide range of nanomaterials, such as silver, gold, metal oxides, and carbon-based structures, promise a lot, a lot of questions have been raised on their compatibility in the long term, their impact on the environment, and their legality. Nanotechnology, coupled with precision medicine and CRISPR-based systems, is a promising future in dealing with infectious diseases. Finally, nanomedicine is a complex solution to address the shortcomings of existing treatments and achieve a future of world health.

Indexed as

Anti-Bacterial AgentsBacteriaBacterial InfectionsDrug Resistance, Multiple, BacterialNanoparticlesDrug Delivery SystemsHumansNanotechnologyOxidative StressAnti-Bacterial Agentsbiofilmcarbon nanotubesclinical trialsdrug deliverygold nanoparticlesnanobioticssilver nanoparticles

Identifiers

PMID42231038
PMCPMC13239940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.